MPLT — MapLight Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $436.00m
- $131.27m
Annual cashflow statement for MapLight Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -30 | -55.7 | -77.6 | -161 |
| Depreciation | ||||
| Non-Cash Items | 1.94 | 0.592 | 1.13 | 35.3 |
| Unusual Items | ||||
| Equity in Net Earnings/Losses | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 0.927 | 2.56 | -3.06 | -12.8 |
| Change in Prepaid Expenses | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Other Operating Cash Flow | ||||
| Cash from Operating Activities | -26.6 | -52 | -78.8 | -138 |
| Capital Expenditures | -0.746 | -0.462 | -0.77 | -0.473 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | — | — | -80 | -323 |
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | -0.746 | -0.462 | -80.8 | -323 |
| Financing Cash Flow Items | — | — | -2.19 | -5.02 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Cash from Financing Activities | 33.2 | 105 | 118 | 470 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 5.85 | 52.1 | -41.5 | 8.48 |